Toll Free: 1-888-928-9744
Published: Jul, 2014 | Pages:
20 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Haemostatix Ltd - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Haemostatix Ltd - Product Pipeline Review - 2014', provides an overview of the Haemostatix Ltd's pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Haemostatix Ltd's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Haemostatix Ltd including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Haemostatix Ltd's human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Haemostatix Ltd's pipeline products Reasons to buy - Evaluate Haemostatix Ltd's strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Haemostatix Ltd in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Haemostatix Ltd's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Haemostatix Ltd and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Haemostatix Ltd - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Haemostatix Ltd and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 3 List of Figures 3 Haemostatix Ltd Snapshot 4 Haemostatix Ltd Overview 4 Key Information 4 Key Facts 4 Haemostatix Ltd - Research and Development Overview 5 Key Therapeutic Areas 5 Haemostatix Ltd - Pipeline Review 7 Pipeline Products by Stage of Development 7 Pipeline Products - Monotherapy 8 Haemostatix Ltd - Pipeline Products Glance 9 Haemostatix Ltd - Early Stage Pipeline Products 9 Preclinical Products/Combination Treatment Modalities 9 Discovery Products/Combination Treatment Modalities 10 Haemostatix Ltd - Unknown Stage Pipeline Products 11 Unknown Products/Combination Treatment Modalities 11 Haemostatix Ltd - Drug Profiles 12 HaemoPlax 12 Product Description 12 Mechanism of Action 12 R&D Progress 12 HXTC-901 13 Product Description 13 Mechanism of Action 13 R&D Progress 13 PeproStat 14 Product Description 14 Mechanism of Action 14 R&D Progress 14 Haemostatix Ltd - Pipeline Analysis 15 Haemostatix Ltd - Pipeline Products by Target 15 Haemostatix Ltd - Pipeline Products by Route of Administration 16 Haemostatix Ltd - Pipeline Products by Molecule Type 17 Haemostatix Ltd - Locations And Subsidiaries 18 Head Office 18 Appendix 19 Methodology 19 Coverage 19 Secondary Research 19 Primary Research 19 Expert Panel Validation 19 Contact Us 20 Disclaimer 20
List of Tables Haemostatix Ltd, Key Information 4 Haemostatix Ltd, Key Facts 4 Haemostatix Ltd - Pipeline by Indication, 2014 6 Haemostatix Ltd - Pipeline by Stage of Development, 2014 7 Haemostatix Ltd - Monotherapy Products in Pipeline, 2014 8 Haemostatix Ltd - Preclinical, 2014 9 Haemostatix Ltd - Discovery, 2014 10 Haemostatix Ltd - Unknown, 2014 11 Haemostatix Ltd - Pipeline by Target, 2014 15 Haemostatix Ltd - Pipeline by Route of Administration, 2014 16 Haemostatix Ltd - Pipeline by Molecule Type, 2014 17
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.